CG Oncology (CGON) Income towards Parent Company (2023 - 2026)

CG Oncology's Income towards Parent Company history runs 4 years deep, the most recent figure standing at -$443.0 million for Q1 2026.

• Quarterly Income towards Parent Company fell 263.8% year-over-year to -$443.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$867.1 million (down 72.32% YoY) and the FY2025 annual result came in at -$359.4 million, down 83.18% from the prior year.
• Income towards Parent Company was -$443.0 million for Q1 2026 at CG Oncology, down from -$41.5 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$8.9 million in Q1 2023 and bottomed at -$443.0 million in Q1 2026.
• A 4-year average of -$128.3 million and a median of -$121.8 million in 2025 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2024 — Income towards Parent Company slumped 2673.52% — and 2025, when it jumped 50.92%.
• CG Oncology's Income towards Parent Company stood at -$16.6 million in 2023, then sank by 92.52% to -$31.9 million in 2024, then plunged by 30.12% to -$41.5 million in 2025, then plunged by 968.46% to -$443.0 million in 2026.
• Business Quant data shows CGON's Income towards Parent Company at -$443.0 million in Q1 2026, -$41.5 million in Q4 2025, and -$234.4 million in Q3 2025.